A Phase 1, Open-Label, Randomized, Single-Dose, 3-Treatment, 3-Way Crossover, Pharmacokinetic Study to Evaluate the Relative Bioavailability of AB521 Tablet and Capsule Formulations and the Effect of Food on the Pharmacokinetics of the Tablet Formulation in Healthy Adult Volunteers
Latest Information Update: 20 Dec 2024
At a glance
- Drugs Casdatifan (Primary) ; Casdatifan
- Indications Cancer; Liver cancer; Renal cell carcinoma; Solid tumours
- Focus Pharmacokinetics
- Acronyms ARC-28
- Sponsors Arcus Biosciences
- 25 Oct 2024 Results evaluating pharmacokinetics profile of AB521 presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics.
- 30 Oct 2023 Status changed from recruiting to completed.
- 12 Sep 2023 Planned End Date changed from 1 Sep 2023 to 1 Oct 2023.